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While the negative prognostic significance of high blood pressure (BP) in the general population is clearly established, the possible harmful effect of low BP values is still a matter of debate. A recent population prospective observational study, following up >1 million Korean adults for 22.7 million person-years, demonstrated that, while systolic BP was positively related to atherosclerotic vascular mortality when >100 mmHg, the group with systolic BP <90 mmHg had a 1.5 times higher mortality than those with values between 90 and 99 mmHg, thus confirming the existence of a J-curve. 1 This finding was also recently supported by an analysis from the CLARIFY International cohort, including patients with hypertension and coronary artery disease from routine clinical practice. In these patients, systolic BP of <120 mmHg and diastolic BP of <70 mmHg were both associated with adverse cardiovascular outcomes, including mortality. 2 It has been hypothesized that low BP values, and in particular low diastolic BP values, might compromise organ perfusion especially to the brain and the heart, thus precipitating ischaemic events. However, many data suggest that low BP might be a marker of poor health status rather than a mechanism of disease ( Figure 1 ). This issue has been addressed in a prospective study on community residents aged 85 years and older in The Netherlands. The objective was to determine whether the inverse relationship between BP and all-cause mortality in elderly people might be explained by adjusting for health status. The authors found an inverse relationship between BP and all-cause mortality, which disappeared after adjusting for health status variables such as serum albumin, Mini Mental State Examination score, type of residence, cachexia, dependence in activities of daily living. and so on. 3 This ongoing debate is of importance, since it has several implications for treatment strategies in cardiovascular disease. Most of the data on the J-curve phenomenon have three main shortcomings.
i. They come from observational cohort studies. The main consequence is that the risk observed at a given BP cannot be extrapolated to BP values achieved under treatment. ii. The prognostic value of either systolic or diastolic values is analysed separately, which is obviously not physiological. iii. The role of heart failure (HF) is not fully taken into account.
Regarding the first point, at least in hypertensive patients recent evidence seem to suggest that achieving lower BP targets might carry a better cardiovascular protection, as demonstrated by the SPRINT trial 4 and by the recent meta-analysis of 19 trials including 44 989 hypertensive patients, randomized to more or less intensive BPlowering regimens and followed-up for 3.8 years. Patients in the more intensive BP-lowering treatment group, having mean BP levels of 133/76 mmHg, compared with 140/81 mmHg in the less intensive treatment group, had a lower rate of major cardiovascular events, myocardial infarction, and stroke. 5 Regarding the second point, some interesting reflections arise from a recent analysis from the ARIC (Atherosclerosis Risk In Communities) cohort, showing an increase in subclinical myocardial damage accrual and cardiac events in individuals with diastolic BP <60 mmHg, particularly when systolic BP was >120 mmHg. 6 Low diastolic BP accompanied by high systolic BP is a hallmark of large artery stiffness and arterial ageing, and thus may represent per se a negative prognostic factor related to structural, irreversible alterations. Treatment of this category of patients is very challenging, and to date we lack specific therapeutic weapons to reverse the arterial ageing process. 7 As far as the latter point is concerned, subclinical or overt HF may underlie the inverse relationship between BP and mortality seen in observational studies in the general population and in particular in the elderly. 8 Low BP in HF represents a proxy for low cardiac output and impaired organ perfusion. 9 As highlighted by data from the Organized 
Program to Initiate Lifesaving Treatment in Hospitalized Patients with
Heart Failure (OPTIMIZE-HF) registry, patients hospitalized for acute HF with systolic BP at admission <120 mmHg had an about three times higher rate of in-hospital and post-discharge mortality in comparison with those with systolic BP >140 mmHg. It is noteworthy that in HF patients with severe left ventricular dysfunction, the relationship between systolic BP and outcome is linear, suggesting that in these individuals systolic BP is mainly an expression of reduced stroke volume. 10 However, even anaemia and low cholesterol are independent predictors of mortality in patients hospitalized for acute HF, raising the possibility that together with low BP they may all represent markers of cardiac cachexia. 11 Since most of the drugs for which a reduction in mortality in HF patients has been demonstrated also reduce the BP, it is crucial to understand whether the increased mortality associated with low BP occurs despite optimal medical treatment or because of medical treatment. This is an extremely important issue, since low BP might limit the use of life-saving drugs exactly in those patients in which their use might be more beneficial. In this framework, the post-hoc, exploratory analysis of the Prospective Comparison of angiotensin-receptor blocker neprilysin inhibitor with an angiotensin converting enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF), published in this issue of the journal 12 is particularly relevant. In the PARADIGM-HF study, treatment with sacubitril/valsartan reduced the primary composite endpoint of cardiovascular death or HF hospitalization by 20% in comparison with enalapril, on top of optimal treatment, in patients with HF with reduced ejection fraction. 13 Sacubitril/valsartan acts by both inhibiting the renin-angiotensin system and enhancing the activity of natriuretic peptides and bradykinin: thus it not surprising that BP reduction achieved in the PARADIGM study was 5 mmHg greater in the treatment arm than in the control arm, regardless of BP at enrolment. The main finding of the study is that the benefit of treatment with sacubitril/valsartan is constant in all the categories of baseline systolic BP, though patients with low BP showed a higher mortality in comparison with the other BP categories. This finding confirms the hypothesis that low BP identifies a subgroup of HF patients at higher risk per se: optimal treatment in this subgroup carries a great benefit in terms of cardiovascular prognosis. Thus the physician should be reassured that he should not avoid prescribing life-saving treatments in HF patients because he is worried that drug-induced lowering BP might worsen their prognosis. This conclusion is reinforced by an additive analysis performed by Böhm and co-authors, including time-updated BP (which is the last systolic BP at the time point closest to an event or at the end of the study) and BP changes over time instead of baseline BP. These results, though with all the limitations of a post-hoc, explorative analysis, confirm that sacubitril/valsartan maintains its beneficial effect even in patients achieving systolic BP <110 mmHg with active treatment. Though these results have been obtained with sacubitril/valsartan treatment and thus cannot be extended to other drug treatments, they provide novel and important information in the direction of safety of several BP-lowering drugs in the management of HF patients. Unfortunately, the study did not provide data about the impact of HF treatments on diastolic BP, which is critical for coronary perfusion and thus will be particularly important especially in HF with ischaemic aetiology.
Interestingly, patients with low BP at baseline were younger, with a lower ejection fraction, and less likely to have an ischaemic aetiology or a history of diabetes or hypertension. Furthermore, they have a longer HF duration despite a better New York Heart Association class. Thus, the subgroup of patients with HF and low BP might present a worse prognosis in comparison with the other groups due to the different aetiology rather than because of a direct deleterious effect of low BP per se. The demonstration of safety and efficacy of sacubitril/valsartan even in this high-risk group, provided by Böhm and co-authors in this article, 12 might thus modify the therapeutic strategy towards a more intensive treatment. Indeed, though study drug dose reduction and discontinuation for hypotension was more frequent in patients with a low systolic BP at baseline, it reaches 1.3% and 1.0% in the sacubitril/valsartan and in the enalapril arm, respectively: this very high level of tolerability is reassuring and also focuses attention on the importance of careful titration or discontinuation of other vasoactive drugs with no impact on mortality such as diuretics and nitrates, which was planned in the study protocol. However, it should be noted that only patients well tolerating the drug in the runin period were included in the study: the 84% of patients tolerating the introduction of sacubitril/valsartan without interruption or downtitration in the TITRATION study 14 appears to be more realistic.
In conclusion, sacubitril/valsartan is safe and effective in patients with HF and low ejection fraction even in those with systolic BP <110 mmHg. Data are still missing for patients with HF and preserved ejection fraction, in which less effective strategies to improve outcome are available at present and in which the impact of BP values is more controversial. Figure 1 The mechanisms underlying the J-curve between blood pressure and mortality are still a matter of debate.
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